TheraSyn
Announcing the investor offering for MetaBrake LLC, Placing the first TheraSyn product into clinical development.
- Stage Product In Development
- Industry Other
- Location Buffalo, NY, USA
- Currency USD
- Founded July 2007
- Employees 3
Company Summary
TheraSyn Pharmaceuticals, Inc is an emerging clinical developer of both novel and improved oral medications for treatment of Type 2 Diabetes (T2D) and obesity. The product(s) being developed, Brake™ is the only known oral medication to mimic the curative Roux-en-Y gastric bypass (RYGB) surgical procedure. Our first product is a combination of Brake™ and Metformin, called MetaBrake™
Team
-
Jerome J. SchentagChairman, Managing Partner
Professor of Pharmaceutical Sciences at University of Buffalo, founder of TheraSyn (2007) and MetaBrake LLC (2012)
-
Felix Botelho, MBACEO
30 years of business development experience include Merck both domestically and internationally. Founded several companies with exit as sale to large pharma
-
Paul BaroneCFO
20 years experience in large pharmaceutical management
Advisors
-
DLA Piper LLPLawyerUnconfirmedSchunk Wilson PCAccountantUnconfirmed
Previous Investors
-
University at Buffalo has an equity positionUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.